PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study

• Published in: Blood 2016-12, Vol.128 (23), p.e59-e66
• Main Authors: Bruzelius, Maria, Iglesias, Maria Jesus, Hong, Mun-Gwan, Sanchez-Rivera, Laura, Gyorgy, Beata, Souto, Juan Carlos, Frånberg, Mattias, Fredolini, Claudia, Strawbridge, Rona J., Holmström, Margareta, Hamsten, Anders, Uhlén, Mathias, Silveira, Angela, Soria, Jose Manuel, Smadja, David M., Butler, Lynn M., Schwenk, Jochen M., Morange, Pierre-Emmanuel, Trégouët, David-Alexandre, Odeberg, Jacob
• Format: Article
• Language: English
• Subjects: Biomarkers - blood; DNA-Binding Proteins - blood; Female; Glutathione Peroxidase - blood; Hematology; Human health and pathology; Humans; Life Sciences; Male; Medicin och hälsovetenskap; Proteomics; Proto-Oncogene Proteins c-sis - blood; Risk Factors; Transcription Factors - blood; Venous Thromboembolism - blood; von Willebrand Factor - metabolism
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2016-05-711846

There is a clear clinical need for high-specificity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far, such markers have remained elusive. Utilizing affinity reagents from the Human Protein Atlas project and multiplexed immuoassays, we extensively analyzed plasma samples from 2 individual studies to identify candidate protein markers associated with VTE risk. We screened plasma samples from 88 VTE cases and 85 matched controls, collected as part of the Swedish “Venous Thromboembolism Biomarker Study,” using suspension bead arrays composed of 755 antibodies targeting 408 candidate proteins. We identified significant associations between VTE occurrence and plasma levels of human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1), von Willebrand factor (VWF), glutathione peroxidase 3 (GPX3), and platelet-derived growth factor β (PDGFB). For replication, we profiled plasma samples of 580 cases and 589 controls from the French FARIVE study. These results confirmed the association of VWF and PDGFB with VTE after correction for multiple testing, whereas only weak trends were observed for HIVEP1 and GPX3. Although plasma levels of VWF and PDGFB correlated modestly (ρ ∼ 0.30) with each other, they were independently associated with VTE risk in a joint model in FARIVE (VWF P < .001; PDGFB P = .002). PDGFΒ was verified as the target of the capture antibody by immunocapture mass spectrometry and sandwich enzyme-linked immunosorbent assay. In conclusion, we demonstrate that high-throughput affinity plasma proteomic profiling is a valuable research strategy to identify potential candidate biomarkers for thrombosis-related disorders, and our study suggests a novel association of PDGFB plasma levels with VTE. •High-throughput affinity plasma proteomic profiling can identify candidate plasma biomarkers for VTE.•Elevated plasma PDGFB levels are identified as associated with VTE in 2 independent case control studies.